Amsterdam UMC Imaging Center

Collaboration model

We encourage closer cooperation

Our collaboration model consists of different stages, which can partly be executed in parallel, each one entailing a streamlined and cooperative procedure in order to fine-tune collaboration. 

We encourage closer cooperation between companies and the different disciplines and research institutes involved in healthcare and research, to stimulate and accelerate innovation. Our collaboration model is made up of different stages, which can partly be executed in parallel, each one entailing a streamlined and cooperative procedure in order to fine-tune collaboration between customers, suppliers, and experts, and to optimize the transition between the various stages.

From the first encounter to the signing of an agreement

In our vision, attaining achievements entails successfully working together on drug development in a streamlined and transparent manner. Our cooperation agreements are clear and realistic, in order to stimulate collaboration with and between partners and to operate as smoothly as possible. A legal expert and business developer from our Industry Alliance Office will support partners in this process, from the initial contact and signing of a cooperation agreement to the pairing of specific needs, thereby supporting all stakeholders during the negotiation stage. We respect our partners and will do everything we can in order for them to succeed. It is in our interest, as much as it is in theirs.

Defining mutual expectations. Including added value, time lines, budget, communication and contracting procedures, third party involvement and teams.

To streamline this process, business developers and legal specialists of Innovation Exchange Amsterdam will be involved.

Defining which crucial information about a therapy like a new drug of cell therapy and its target can be obtained by radiochemistry and imaging, taking clinical needs as starting point.
Defining a (radio)chemical strategy to inertly label the medication in question.
Defining the pharmaceutical conditions for the manufacturing of the radiolabeled medication, and the requirements and tests for its release.
Defining which preclinical in vitro and in vivo studies can contribute to the characterization of the (radiolabeled) drug.
Defining a strategy for GMP production of the radiolabeled drug, in close cooperation with partners’ CMC team and our QA team (for auditing).
Defining which method qualifications, validation labeling, quality controls and stability tests have to be performed.
Defining a clinical trial protocol in which tracer imaging and quantification gives optimal insight in drugs’ potential and optimal application.
Defining a smooth procedure for the submission of the IMPD and the clinical protocol to the Medical Ethical Committee (METC).
Defining an optimal work flow for patient inclusion, clinical handling and data management.
Dedicated image data analysis allowing quantitative PK/PD modeling and image interpretation.
Defining what can be learned from imaging results related to other clinical data. Concluding what can be learned from subsequent clinical trials and optional external expertise.